Despite Solid Q3 & Outlook, Rent The Runway Analyst Slashes Price Target By Half Citing Macro Uncertainties

Telsey Advisory analyst Dana Telsey reiterated an Outperform rating on the shares of Rent The Runway, Inc. (NASDAQ: RENT) and reduced the price target from $8 to $4.
  • Telsey Advisory analyst Dana Telsey reiterated an Outperform rating on the shares of Rent The Runway, Inc. (NASDAQ:RENT) and reduced the price target from $8 to $4.
  • The company reported a 3Q22 adjusted EBITDA of $6.6 million versus $(5.6) million last year, well ahead of the market’s expectation of $1.3 million.
  • The upside was driven by stronger topline growth and better gross margin in the period, the analyst noted.
  • Total revenue increased 31.2% to $77.4 million, above the consensus of up 24.2% to $73.3 million and guidance of $72.0 million – $74.0 million. 
  • Gross margin expanded 740 basis points to 41.1%, ahead of the consensus of up 300 basis points to 36.7%, while total operating expenses leveraged 3,270 basis points to 76.0%.
  • The analyst said with the stronger Q3 results and modestly better Q4 guide, RENT raised its annual outlook for both total revenue and adjusted EBITDA margin.
  • With the recently announced restructuring plan largely complete, the company is seeing benefits to profitability, helping drive the third quarter outperformance and a better-than-expected outlook.
  • The analyst sees RENT as well positioned to capitalize on significant secular consumer trends with the potential to drive long-term growth.
  • Meanwhile, the analyst reduced the price target to reflect a more rational multiple given near-term macro uncertainties.
  • Price Action: RENT shares are trading higher by 72.1% at $2.34 on the last check Thursday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

Catalyst Biosciences Announces Completion Of Business Combination With Beijing Continent Pharmaceuticals And Implementation Of Name Change And 1-For-15 Reverse Stock Split; Company Will Operate As Gyre Therapeutics, Inc. Under Trading Symbol “GYRE”

The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) --

CBIO